Agoracom Blog Home

Posts Tagged ‘COVID-19’

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Provides BioCloud Update and Enters into Distribution Agreements $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:14 AM on Wednesday, November 18th, 2020
kontrol-logo

Safe Space Technology

  • Company intends to sell BioCloud directly to various potential customers. At the same time the Company is pursuing both exclusive and non-exclusive distribution channels for BioCloud sales
  • Entered into two non-exclusive BioCloud distribution agreements
  • Distribution agreements cover Ontario and Saskatchewan
  • Kontrol Energy Corp. is in the process of changing its name to Kontrol Technologies Inc.
  • The name change is anticipated to take place by the end of December 2020
  • As of November 17, 2020, the Company has $3.8 Million of cash on hand

TORONTO, ON / November 18, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its BioCloud technology development.

“Our team continues to execute on the vision to create and bring to market a safe space technology,” says Paul Ghezzi, CEO of Kontrol.

Distribution Agreements

The Company intends to sell BioCloud directly to various potential customers. At the same time the Company is pursuing both exclusive and non-exclusive distribution channels for BioCloud sales. Kontrol is pleased to announce it has entered into two non-exclusive BioCloud distribution agreements. The distribution agreements cover Ontario and Saskatchewan.

The Company has also entered into discussions with various parties for potential industry exclusive distribution agreements which would require minimum unit quantity orders.

New Website

Kontrol has launched a new website for BioCloud. For more information please visit www.kontrolbiocloud.com.

Name Change

Kontrol Energy Corp. is in the process of changing its name to Kontrol Technologies Inc. The name change is anticipated to take place by the end of December 2020.

Cash on Hand

As of November 17, 2020, the Company has $3.8 Million of cash on hand.

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE:KNR)(OTCQB: KNRLF)(FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.


Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

CLIENT FEATURE: Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Technology To Detect #COVID-19 In The Air $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 2:25 PM on Tuesday, November 17th, 2020
kontrol-logo

Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.

As a result, Kontrol is already achieving commercial success as follows:

  • Q1 $2.3M
  • Q2 $2.7M

TOTAL Q1 AND Q2

  • REVENUE                 $5M
  • GROSS PROFIT        $2.7M

ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS

As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.

GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH

Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.

The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:

Early tests suggest new Canadian technology could detect the coronavirus in the air Read More

Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.

Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More

CSA APPROVAL RECEIVED ON NOVEMBER 5TH

On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

For more information about the company, please check out the Kontrol Energy hub on AGORACOM.

FULL DISCLOSURE: Kontrol Energy is an advertising client of AGORA Internet Relations Corp.

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Presenting at The Virtual Fall Investor Summit $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:38 AM on Monday, November 16th, 2020
kontrol-logo

TORONTO, ON / November 16, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) today announced that CEO Paul Ghezzi will present to investors at the Virtual Fall Investor Summit on Wednesday, November 18, 2020 at 4:00pm EDT. Participants can listen to Kontrol’s presentation at https://www.webcaster4.com/Webcast/Page/2038/38778. As facilitated by the conference, Kontrol will also participate in scheduled meetings.

“Kontrol Energy continues to build upon our base business that addresses the growing problem of energy waste, greenhouse gas emissions and air quality in the building sector,” said Mr. Ghezzi. “Kontrol has recently announced its plans to commercialize the Kontrol BioCloud analyzer (or BioCloud). BioCloud is a real-time viral detection technology. We look forward to connecting with the Virtual Fall Summit community.”

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

Kontrol BioCloud is not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE:KNR) (OTCQB:KNRLF) (FSE:1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at http://www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer [email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

About the Fall Investor Summit Conference

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker ([email protected])

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at [email protected]

News Compliments of ACCESSWIRE

SOURCE: Kontrol Energy Corp.

6 Small Cap Stocks That Are Providing Real Products and Solutions In The Fight Against #Coronavirus #COVID19 $DM.ca $CBDT.ca $INNO.ca $KNR.ca $MTRX.ca $PRMO.ca

Posted by AGORACOM-JC at 12:18 PM on Thursday, November 12th, 2020
What do you call the disease caused by the novel coronavirus? Covid-19

The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here. 

What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible. 

Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.

There are no magic bullets.  COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders.  This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.

Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.

Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution.  When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.

REVENUE $CAD

Q1 + 62% To $809,000

Q2 + 419% To $1,954,000

TOTAL Q1 AND Q2

REVENUE     $2.8M vs $875K = +220%

GROSS PROFIT $1.2 vs $739K = +62%

Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;

  • Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
  • Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
  • $20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
  • Received Third COVID-19 Order from TV Production Company (September 21, 2020)
  • Received  COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)

··      The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.

The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.

For more information, please visit the Datametrex AI hub on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:  

  • Increased CBD treatments from patients suffering increased anxiety;
  • Covid-19 Testing for individuals and families
  • Covid-19 Testing for local businesses and employees 
  • Covid-19 Testing for enterprise level organizations across the country 
  • Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 RT-PCR tests per day. RT-PCR tests are considered the gold standard of COVID-19 testing

How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.

Patient Visits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth. 

For more information about the company, please check out the Empower HUB on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.

Why is this significant?

CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.

Superior Management Team

More than just lip service, Innocan has a world class management team to make this happen.

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world

Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)

Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.

Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

To support this global growth, Innocan already has the following relationships in place:

Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)

Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)

Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.

As a result, Kontrol is already achieving commercial success as follows:

·         Q1 $2.3M

·         Q2 $2.7M

TOTAL Q1 AND Q2

  • REVENUE                 $5M
  • GROSS PROFIT        $2.7M

ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS

As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.

GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH

Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.

The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:

Early tests suggest new Canadian technology could detect the coronavirus in the air Read More

Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.

Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More

CSA APPROVAL RECEIVED ON NOVEMBER 5TH

On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

For more information about the company, please check out the Kontrol Energy hub on AGORACOM.

Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.

Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses.  More than just lip service, Loop has already announced significant partnerships and news with the likes of:

TELUS  

Loop was recently accepted into the TELUS IoT Marketplace for national sales and marketing to TELUS business Customers

Andrew Turner, TELUS VP Strategic Operations,

“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.” 

AMAZON 

On October 29th, the Company announced that Amazon Web Services (AWS) and Loop Insights would be hosting an interactive webinar to showcase the Company ‘ s Venue Tracing Solution to a global audience of businesses to learn about the technical, security, privacy, and commercial aspects of Loop ‘ s Venue Tracing Platform. 

The invitees were from industries including but not limited to: 

  • Airlines
  • Venue Owners
  • Sports & Entertainment
  • Telecom
  • Government

How did the webinar go?  On October 30th Loop announced Early Response To Amazon Web Services And Loop Insights Showcase Of Loop Venue Tracing Solution To Global Audience Indicates Great Success

The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.

Loop Insights CEO Rob Anson:

“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”

In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:

  • Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
  • Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
  • Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
  • Implemented By University Of Houston  (September 16, 2020)
  • Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
  • Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)

For more information about the company, please check out the Loop Insights hub on AGORACOM.

Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.

Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.

The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.

The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U

The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.

For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.

Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small_Cap_Coronavirus_Covid-19%20

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:14 AM on Thursday, November 12th, 2020
kontrol-logo

Kontrol BioCloud a Safe Space Technology

  • Received UL standards approval for its BioCloud® technology
  • As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
  • “We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

Field Certification was provided by ESAFE

Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives CSA Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 1:54 PM on Thursday, November 5th, 2020
kontrol-logo

 Kontrol BioCloud® a Safe Space Technology™ –

  • Announced that it has received CSA standards approval for its BioCloud® technology
  • “This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol
  • CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety

TORONTO, ON / ACCESSWIRE / November 5, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

Field Certification was provided by ESAFE

CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety. The field evaluation process follows the CSA’s SPE-1000 standard, which has three mandatory and non-destructive tests. Upon successful inspection, ESAFE validates the equipment meets CSA’s SPE-1000 standards and labels it approved. ESAFE’s labels are recognized across Canada under the Standards Council of Canada accreditation program.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com.

Image: https://www.accesswire.com/users/newswire/images//10252018KNR2.pngImage: https://www.accesswire.com/users/newswire/images//10252018KNR3.pngImage: https://www.accesswire.com/users/newswire/images//10252018KNR4.png

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud® Analyzer are subject to the risk that the Kontrol BioCloud® Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 5:51 PM on Wednesday, November 4th, 2020
Innocan-Blog
  • InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
  • The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
  • From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research

By: Liz Scherer

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).

There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).

Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.

Why CBD and Why Now?

CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.

CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.

The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.

Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.

Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Establishes Lower Detection Limit for Commercialization of BioCloud $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:35 AM on Thursday, October 29th, 2020
kontrol-logo

Kontrol BioCloud a Safe Space Technology™

  • Provides an update on lower detection limits and commercialization.
  • “We are pleased to continue to advance towards production of BioCloud units in November,” says Paul Ghezzi, CEO Kontrol. “The lower detection limit is an important benchmark to provide potential customers with the operating sensitivity of BioCloud.”
  • As part of its commercialization of the BioCloud technology, Kontrol has currently established a lower detection limit of 50 SARs-COV-2 virus particles
  • This represents a sufficient sensitivity to the SARS COV-2 virus for commercialization

TORONTO, ON / October 29, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its Kontrol BioCloud (or “BioCloud“) technology. As initially referenced in the press release from September 10, 2020 Kontrol is providing an update on lower detection limits and commercialization.

Lower Detection Limit

“We are pleased to continue to advance towards production of BioCloud units in November,” says Paul Ghezzi, CEO Kontrol. “The lower detection limit is an important benchmark to provide potential customers with the operating sensitivity of BioCloud.”

As part of its commercialization of the BioCloud technology, Kontrol has currently established a lower detection limit of 50 SARs-COV-2 virus particles. This represents a sufficient sensitivity to the SARS COV-2 virus for commercialization.

The determination of lower detection limit was tested under independent laboratory conditions over multiple tests. The BioCloud virus collector was exposed to live SARs-COV-2 virus (virus that causes COVID-19) at multiple levels of virus ranging from 10,000, 5,000, 1,000, 100, 50 and 5 viruses. These tests were conducted multiple times to ensure repeatability of the response, and under laboratory conditions the detection of the live SARs-COV-2 virus was repeatably identified at 50 virus particles.

Commercialization

Based on feedback from potential customers and potential distribution channels Kontrol is seeking multiple certifications concurrently to meet regional requirements. These include CSA, CE and UL. CSA is a Canadian certification; CE mainly applies to European electronic products and UL is typically required in the USA.

Balance Sheet

Kontrol currently has approximately $3.0 Million of cash on hand as of October 28th, 2020 and has sufficient resources to complete the commercialization of BioCloud.

National Research Council of Canada

Kontrol has submitted all of its required research and files for potential National Research Council of Canada funding.

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

VIDEO – Loop Insights and Empower Clinics Team Up To Create First Ever “Travel Bubble” Solution For Global Travel Industry

Posted by AGORACOM-JC at 11:30 AM on Tuesday, October 20th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

Welcome to beyond the press release of production of AGORACOM which we speak the small cap executives right after they put up for news today we’ve got not 1 but 2 companies on Empower Clinics trade on the CSE and the stock symbol CBDT and the U. S. under EPWCF we got Steve McAuley of Empower Clinics for those who knew the story that’s gonna be a lot you can get a lot of market attention a vertically integrated health and wellness company their server database but 165,000 patients through clinics in the southwest US plus a telemedicine platform and a world class medical diagnostics lab more than just lip service they’ve out they’ve shown continued growth on patient revenue income side for Q. 4 Q. 1 Q. 2 the other company with us Loop Insights trades on the stock symbol M. T. R. X. and for friends the U. S RACMF a provider of contactless solutions and artificial intelligence to drive real time insights enhance customer engagement automated contact tracing to the brick and mortar space again more just lip service there they’ve had tremendous success also just recently announced a great agreement would tell us we’re going to resell their their products all over Canada Vegas bubble were gonna be providing venue tracing a contact based solutions as well as are a number of other ones they rob believe what you guys have been able to do in the last 30 days. The headline we’re talk about today these companies have combined venue tracing with Covid-19 expertise to create the first ever travel bubble solution for the global travel industry that’s set to lose 3B, gentleman welcome to the show. George thanks for having us.  Guys this is a great press release in fact it’s almost unimaginable how big this is the 2 Canadian small cap covers gonna be able to tackle it before getting some the details you guys are 2 parts of this troubled solution so let’s walk through it briefly so people understand how this practically applies to the let’s start with the loop because you’re the front end facing part of the solution rob so maybe you can walk through that and they will move on to start a Steve on the Empower side with the Covid 19 testing part. Sure and and I’ll use the airline San Juan to Sam I guess with the cruise ships but. The challenge right now is our government needs to wake up I mean Dam they’re shutting down economies one of the only countries I’m not blaming Canada. But you know then to have no plan in place to eliminate the 14 day quarantine is absolutely absurd you know now there’s articles coming out that the Canadian government’s looking to buy a position. So I’m not really sure what agenda our government’s looking out for but it’s most definitely not about small business and that’s a fact so providing their lines the cruise ship the hospitality industry the ability to re open now is what Empower so in our case we have an end to end solution for tracing for payments for contactless engagement as we’ve talked about before when you add now the power of what Empower in the lab testing capabilities there is no need for 14 day quarantine. The minute that that you know person comes off the plane there’s ability now to have testing set out that complete security around all of the results and I have anonymity and what I mean by that is right now all of these news articles and I keep reading and on the on the radio on global too in other news at 90. It’s just a cry and it’s Hey we’ve had exposures come out by us and you know everyone just gets more anxious there’s no need for that with our platform the audience is 100 percent segmented and it’s only notified directly to your phone whether it’s an email a voice call whatever it may be there’s no need for this generalized red alert oh my goodness. Steve your side is the testing side which is easier obviously equally critical this because with loops are I’ve got on my phone it’s a wallet pass I can get on the plane I could be identified I can be alerted. Where does Empower fit in all this. Yeah this is this is a great partnership for us I mean we have been spending some time working with rob and his team going through the platform and understanding and I could tell you on this is state of the art technology on its effective but most importantly it’s simple and it’s it’s easy to use that’s functional so when we think about what our strengths are so think of the supply chain of testing so there’s the front and specimen collection however that might take place in and you’ve seen without prior releases you we are now you’re deep in our 4 stage national rollout of our testing platform but then the others great asset that we have in our books now is trying medical laboratory it has the capability of not only providing rapid tests are to be deployed at point of collection but also to do the back and PCR testing of which we can process for thousands of specimens per day right now that’s our current capacity so given the capacity that we have the scientific expertise having the ability to run the specimen collection at points all of us at that point all with the patients or the consumer might be and then combining with large testing capability we think putting the 2 yes assets together is it is a tremendous solution to help open up the economy and Steve you say simple and easy but that’s only because you made it simple and easy it’s not something very many companies can do don’t don’t sell yourself short that’s for sure. Rob I’m gonna go I’m gonna take a excerpt from the press release here because this is not just too small cap companies getting together and saying Hey let’s slop or solution together and see we can come up with a quote the company advises discussions are already underway with major airlines cruise ship operators and hotel rob can you give us a little bit of insight into what those conversations are looking like what the urgency is like and the acceptance of of this travel bubble solution. Sure it says its dynamic because there’s just so many so many challenges right now George we got boats that are traveling around the ocean empty you’ve got airlines that are struggling to gain confidence you’ve got people that are looking to go you know see family I mean I’ve I’ve got a buddy his you know down in the US is on his deathbed love not not nothing more to go see him but. 14 day quarantine. Like it’s it’s it’s asinine so the challenges are all everybody and it’s not just these these industries here the mom and pop grocery store and convenience store on the corner everyone has to remain remain open. Where where today in an article here with Steve is. To put a plan in place to present. Container again to the government to show them exactly now how we can reopen the private sector because right now putting your head in the sand sending everybody home for 2 weeks again in Toronto is doing anything that there’s still no good at all sell resulting in factors be there either protest mystery now people saying you were just not going to do it it is it’s nonsense and you know the next couple weeks here I think you’re absolutely imperative from government and to see someone stuff up Alberta is is starting to be some of that article when their health minister I mean they’re even more rougher shape so it’s not going anywhere putting that in the sense not solving anything so we’re providing them a turn key solution that starts that can be replicated over and over and over. So it’s not just airlines and cruise ship operators talk to but also governments that these discussions about it and if you don’t mind can you give us a sense for what those conversational like are they well advanced on the right the very beginning and what is what’s the what’s the excitement on the other side that you you guys may have a solution. Well I mean to be honest with you and of course I can’t say too much but that were way down the path we know that’s not a surprise to anyone you know they’re there the belief that the federal tracing apps gonna solve all the problems we know that’s not reality we all knew was gonna take a multitude of solutions and the private sector is going to play a big part of that I mean this this look back in time for decades and decades this is not a surprise to anyone so we’re way way down the path of the escalation of called it in phase 2 phase 3 depending upon how you’re talking to is here upon us and inevitable to grow look at the global numbers in the press release how many countries are shut down it’s not just here in Canada this is a global issue. On that note Steve there is also part of the press which word you guys make a joint statement says  empower believe the travel bubble combination of frequent testing robots in national trade platform provides the antenna production nested to spark a strong global economic recovery I mean you know that’s all I’m gonna play devil’s advocate say that almost seems too good to be true but the fact of matter is someone has to save the day and someone has to save the world at the end of the day and looks like it it may be you guys can you speak more to that as to you know whether that’s done almost intimidate you as the as the size of the problem or your confidence level that yeah we can actually solve this. It did the size of the problem is has incredible magnitude it doesn’t necessarily intimidate us all we know we can’t solve every country’s problems are but we know that we can definitely get to private sector public sector and bring this solution to the table as as rob and I were discussing you know how to put an implementation plan in place yeah we quickly realized that we’re both having independent conversations with small medium and large entities and if we could cross reference those opportunities and bring in more viable young cohesive solution together because you need contact tracing and testing you know one without the other isn’t a complete solution so again it was really relatively obvious for us that if we can find a way to really collaborate and work together we got a fighting chance to make a difference and to make an impact we think we can make a scalable impact on to this right now it’s about getting awareness out but I can tell you that I go right from this call into a large group that owns elder care facilities in all the southwest United States there are thousands of patients and their families that are impacted just by this one conversation that I’m having rocks having the same conversations with large organizations like U. N. C. to weigh in and the tech bubble is coming up and will be on the bubble is coming up in Las Vegas we’ve already been in discussions with cruise lines we know that rob’s been in discussions with cruise lines so as your rob used the word dynamic a little bit earlier that’s what it’s like for us right now it’s it’s it’s kind of wild and dynamic and crazy but we’ve got a solution that we believe is extremely viable and is going to make an impact to getting this economy back up and running Hey rob is a tiny perfect here because if you guys try to you know do. This 6 months ago you would have had tell us third party validation the Vegas bubble for the NC double a the university of Houston Steve would have had the time to show Q. 4 Q. one Q. 2 growth the acquisition of this massive lab in Dallas Texas right in the heart of the medical world there so when you’re having these conversations how much does your success with some of these names come into play because I got assume that’s very important  just can’t come along so we got a solution even if we have it. This that faith in conference might not be there but you guys have it because of you’ve got third party validation. What is time is everything in business and life and it’s much like our ticker symbol people always ask me what is matrix as evidence the watch the movie everything always happens for a reason and you know let’s say 7 not that I’m taking credit for you know cold it but its foresight around digital transformation and you know what without a transformative solution or future proof roadmap we’re gonna be hung out here high and dry for decades to come the financial burden that this is put on by the Canadian population areas it’s it’s still it’s sickening and then out there’s no need to go hire more people throw more money at it this is what artificial intelligence and automation is about. Is about machine learning it’s about managing these processes like we build here was Steve. It it’s it’s it’s a little frustrating they can tell their yeah I’d like to tell you are we all are on I’m glad yeah I think it right it is and you know right now is the perfect timing and like I said when. When when we get in these conversations we deliver and at the end of the day you know there’s a a global problem anyone just punching Covid-19 revolt protest whatever maybe I mean you see videos of you know cities burning burned down again I mean it’s it’s it’s rather alarming at its time here that groups like Empower and Lop come together and deliver something that’s. Black and white in front of them here we go Steve is it fair to say that in phase one. We’ll put their faith in government to do the right things and help us get through all this but now in phase 2 are you hearing from you know you are you said useful to cruise ship operates for example and many other major film studios I mean you you’re you’re you you’ve already announced testing for major film studio we already know that is it safe to say that enterprise is much more willing now in fact almost demanding that you guys come forth with the solution because they’ve lost the faith in government. Well I mean I think to keep in mind here the markets you know my current law on major markets are in the US and the US are doesn’t have a cohesive federal strategy to address these issues that we’re talking about right now even at the state level state by state their success or failures very dramatically but there is one consistency in the United States in all states the numbers are out of control again and they’re not getting worse they’re not getting better getting much worse for sure there is our first region there is dissent I’m at all levels and the other thing is happening now in the U. S. this is becoming a legal matter you know we see our society the U. S. as more litigious than perhaps we see back home here to Canada all but we’re we’re seeing and we’re hearing not and to go but we have have not see this going on is that employers are getting sued by employees if that employer is not demonstrating that they’re doing all they can to provide protect or provide health and safety not only for employees but for customers and vendors so you’ve got industries now that are all putting regulation and so if you take film and television you’ve got the screen actor’s guild who are dictating policy if you look at the cruise ship industry the our cruise line international H. R. association are established policies for cruise lines going forward which say all crew staff and passengers must produce a negative coping 19 task 5 days before boarding or they will not be able to board and indeed a very comprehensive contact tracing solution just to pull it all together make it work so is becoming regulated now whether. Federal government’s comment or state governments come in is almost irrelevant at NY times the big industries are now legislating themselves to bring these solutions to market. Hey Rob any decision like this still comes down ROI no matter what money still matters at the end of the day we know the bad though the losses are massive you gave in to you do you get anything stop the other day off on a call about just how much the Ontario or the Canadian government was losing from foreign students not being able to be here talk a little bit to that if you don’t mind and then does that mean does that give you guys pricing power down today because of the losses are so massive known to be bickering over cost they just want a solution to get back to business. Well most definitely I mean no matter what angle you look at it whether it’s from a federal government standpoint. The impact by not having students foreign students attending school in Canada this year will surpass 1B so just think about not just that’s just foreign students. Looking to still reside in Canada to go to university. The numbers are absolutely staggering. Sell side you know I said to you Hey George I can make your headache go away instantly across on $1000000 and look at the numbers you’ve got last. I mean. You know what is some of what is the what is the value that’s what someone’s willing to pay. And right now we’re we’re in a very strong position. And you know it’s the same side of it my my call before this one was one of the major universities in in the south we’re at 50 percent capacity for the ball season coming up. We have very limited revenue now because of it they’re all not just looking for today George in the US where we’re seeing these large enterprise organizations are looking for 2021-2022. 3 year roadmap because they understand this is not going anywhere just like 911 changed the way security and travel covid pandemic right now is forcing digital ID digital wallets and the complete end to end solution so you’re gonna see testing. I guarantee you you mark my words you will see testing in every major airport in our country in the next 6 months to one year. Do you think you guys play a major role in that Steve and rob do you guys think that you know if you’re able if you got this travel bubble that did you guys be a big part of that well I think part of it and once again I think that that’s the reason easy answer yes we’re going to be a part of this for sure you know the the the volume and scale this is substantial and to the extent that we can you know from a business perspective in our partnership I gain some of that market share then I think people are going to quickly realized that we have that capability we have the operational skill set we have the sciences and the diagnostic testing capability and we have an elegance A. I. driven solution for contact tracing so I definitely think that we can play a role in that part of it but as we’ve been discussing here there are so many large assets not for us to to talk about you know we together you know we are already you know independently talking to your division one universities and colleges in the states and their athletic programs you know some of these big division one colleges you know they have their generate in excess of $1B U. S. on their programs per year so that is a significant revenue that has been lost and they’re not going to regain it that’s read on walks so now is as we’re rob says. How are they going to plan to resolve this business problem that they have in years ahead there to figure out how to regain it in a safe and healthy manner again for all of the people who are in their system your players and coaches and staff but also the fans and without the fans attending then they really can’t generate the revenue streams that they they normally expect. Jets jets I know you both have I mean you’ve done it everyone a great service here by jumping on the middle day you both have hard stops in 2 minutes which is great because you speak to potential customers so rob maybe I’ll ask you is it is it safe to assume that you know you can expect to see some kind of uptake commercialization coming out of this. In the near future or is it still going to be up a long sales cycle in order to get this done. No I I think it’s it’s it’s very near I mean that. The the the thing that we’ve built here George this can be replicated in every city across the world I mean it’s it’s where our data platform that can connect to any lab testing group globally so doesn’t matter which government doesn’t matter it’s private sector independent whatever maybe and so now this is something like this said here that we are we see great opportunity and we’re going after. There’s so much more we could talk about we’re pretty sure the fact the took out your 20 minutes of your time you know the day congratulations.  Pretty soon their future goes sounds like you’ve already got irons in the fire and not your some shareholder point of view but from a system point of view thanks to you guys have done so far and if you can really you know make this happen then you’re gonna be helping out everybody not just financial mental health stress anxiety all that so good luck to you guys and thanks for joining us right thank you George .  you’ve been watching Steve McAauley of  Empower clinics trades on the CSE and the stock symbol CBDT and for a friends of the US under EPWCF. likewise you been watching Rob Anson of Loop Insights trades of TSX venture exchange of the stock symbol MTRX go watch the matrix if you haven’t you can answer the question and for friends the U. S. RACMF thanks for joining us everyone have a great day see you next time.

VIDEO – Loop Insights $MTRX.ca and Empower Clinics $CBDT.ca Team Up To Create First Ever “Travel Bubble” Solution For Global Travel Industry $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 5:06 PM on Monday, October 19th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

The COVID-19 Pandemic has wreaked havoc on the global economy but perhaps no industry has suffered worse than the travel industry which could suffer an unfathomable loss of $US 3.3 TRILLION (Not A Typo) if it can’t find a practical solution to replace the shut down and / or quarantine measures mandated around the world.  Specifically, as of today, travel restrictions by country are as follows: 

  • 58 countries are completely closed
  • 124 countries are partially open with MANDATORY quarantine upon arrival

Unlike the restaurant business which can mitigate losses through alternative models such as take-out, delivery and outdoor patios, the travel industry has no mitigation solutions.  Countries are either shut down or implementing such strict quarantine requirements that they might as well be shut down.  The only solution is a complete solution that combines venue tracing, contact tracing and rapid testing to give government, airlines and cruise ships the comfort they need to know that travellers are not spreading COVID-19 to each other, or to other countries. 

Loop Insights CEO, Rob Anson confirmed this when he said:

“We have heard from stakeholders in the entertainment, travel, and hospitality industries that have stressed the importance of an end-to-end integrated solution capable of protecting employees and customers to facilitate a safe economic recovery.”

ENTER THE “TRAVEL BUBBLE”

Earlier today, Empower Clinics (CBDT:CSE) and Loop Insights (MTRX:TSXV) announced they have combined forces to provide an end-to-end COVID-19 mitigation solution complete with venue tracing, real-time automated guest exposure notifications and frequent testing with rapid results in 15 minutes.  More than just lip service, each company brings a strong recent track record of success in their respective parts of the bubble as follows:

LOOP INSIGHTS

As the front facing part of the Travel Bubble solution, Loop Insights is a powerful Artificial Intelligence company whose industry leading venue tracing has gained significant traction towards reopening the tourism, hospitality and entertainment industries in the United States with the likes of University of Houston and the NCAA Basketball #VegasBubble, as well as, recently being recognized by TELUS as one of the most advanced IoT solutions in the world for their customers.

EMPOWER CLINICS

Empower’s rapid antigen and antibody tests produce results in only 15 minutes, providing airlines, cruise ships and the 182 countries currently in full or partial shutdown with the safety and security necessary to fully reopen their borders to international travel. Moreover, Empower’s KAI Medical Laboratory is a high-complexity accredited laboratory that provides reliable and accurate testing solutions to enterprise level clients, including the gold standard COVID-19 RT-PCR testing  with the capacity to process 4,000 tests per day. Empower recently announced a deal to provide a major film and television studio with 1,000 such tests.

Together, the two companies believe the Travel Bubble combination of frequent testing and a robust international tracing platform provides the end-to-end protection necessary to spark a strong global economic recovery.

Sounds too good to be true?  Both companies still have to execute but they advise that advanced discussions are already underway with major airlines, cruise ship companies and hotel operators.

Watch or listen to this powerful interview with Empower CEO, Steve McAuley and Loop CEO, Rob Anson to learn more about their potential game changing Travel Bubble solution.